AviaraDx to Launch Breast Cancer Prognostic Testing Service in 2006

AviaraDx, which was formerly known as Arcturus Bioscience, said last week in a statement that it intends to begin a prognostic testing service for breast cancer patients with partners in the wake of a study supporting its two-gene profile.

AviaraDx is "expecting our diagnostic licensing partners to launch a testing service based on both biomarkers in 2006" Toni Schuh, the company's CEO, said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.